Skip to main content

Table 2 Antibiotic use over time: total consumption and parameters of the multiple linear regression model

From: Antimicrobial stewardship in high-risk febrile neutropenia patients

Antibiotics

Intercept β0 [CI]

Period 1

Period 2

Total

β1 [CI]

p-value

Total

β2 [CI]

p-value

Aminoglycosides

+ 10.69 [− 44.67; + 66.05]

140

+ 5.77 [− 11.18; + 22.71]

0.45

81

− 5.09 [− 16.90; + 6.71]

0.34

Glycopeptides

+ 142.54 [+ 71.56; + 213.51]

754

+ 2.47 [− 19.26; + 24.19]

0.80

113

− 17.34 [− 32.48;− 2.21]

0.03

Carbapenems

+ 112.95 [− 100.10; + 325.99]

1187

+ 41.78 [− 23.42; + 106.99]

0.17

331

− 47.73 [− 93.15;− 2.31]

0.04

Class 3 β-lactams

+ 39.00 [+ 6.48; + 71.51]

74

− 8.35 [− 18.30; + 1.60]

0.09

52

+ 4.89 [− 2.05; + 11.82]

0.14

Class 4 β-lactams

+ 203.79 [+ 18.64; + 388.94]

1173

+ 12.32 [− 44.34; + 68.98]

0.62

1642

+ 2.49 [− 36.98; + 41.96]

0.89

Fluoroquinolones

+ 43.18 [− 101.31; + 187.68]

85

− 7.32 [− 51.55; + 36.90]

0.71

183

+ 5.99 [− 24.81; + 36.80]

0.66

Daptomycine + Linezolide

+ 6.43 [− 33.54; + 46.40]

56

+ 2.01 [− 10.22; + 14.25]

0.71

37

− 2.05 [− 10.57; + 6.47]

0.59

Cotrimoxazole

+ 32.75 [− 20.97; + 86.46]

286

+ 7.70 [− 8.74; + 24.14]

0.30

86

− 9.48 [− 20.93; + 1.97]

0.09

All antibiotics

+ 1692.82 [+ 1235.32; + 2150.33]

6848

− 105.66 [− 245.67; + 34.36]

0.12

3473

− 19.91 [− 117.45; + 77.63]

0.64

  1. Total antibiotic consumption is expressed in defined daily dose per 1000 patient-days. Raw consumption of daptomycin was 35 DDD/1000 patient-days in both pre- and post-intervention periods. Raw consumption of linezolide was 21 DDD/1000 patient-days in the pre-intervention period and 2 DDD/1000 patient-days in the post-intervention period
  2. CI: 95% confidence interval; Class 3 β-lactams: third-generation cephalosporins or ureido/carboxy-penicillins; Class 4 β-lactams: piperacillin/tazobactam, fourth-generation cephalosporins or antipseudomonal third-generation cephalosporins